Pluri CEO issues letter to shareholders

Pluri (PLUR) issued the following shareholder update from Chief Executive Officer and President, Yaky Yanay: “As we conclude our fiscal year, which was marked by challenges and accomplishments, I’m pleased to share key developments and to outline our path forward… We anticipate that the coming fiscal year will mark a significant turning point, as we unlock the potential of our cell expansion technology to deliver scalable global solutions – particularly in the cocoa and coffee industries, where climate change, plant diseases, and rising demand are steadily increasing shortages… As part of our growth strategy, we have taken steps to strengthen our position in the cultivated cacao space by aligning with an Israeli AgFoodTech company that is developing innovative cell-based cacao technology… In addition, we hold a 69% stake in Ever After Foods Ltd., a private company leveraging Pluri’s cell expansion technology for cultivated meat production… On the medical research front, we received a total of $2.2 million in funding to date from the U.S. National Institutes of Health and the Department of Defense to develop PLX-R18 for the treatment of Acute Radiation Syndrome… In conclusion, we believe that Pluri today operates one of the world’s most innovative and diverse cell expansion platforms, with a wide range of activity in critical sectors. We operate in vast markets characterized by instability and supply chain challenges, and we believe we are uniquely positioned to address these issues. As we approach the end of fiscal year 2025 and the beginning of fiscal year 2026, Pluri moves forward with a solid foundation, strategic partnerships, technological resilience, and a genuine belief in our ability to lead meaningful change in the food and healthcare sectors.”